Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Proteomics Int'l Biomarker Study Closer to Diabetic Kidney Disease CDx Test

Published: Tuesday, April 15, 2014
Last Updated: Monday, April 28, 2014
Bookmark and Share
Company is seeking a commercialisation partner to enter the RUO, LDT or IVD markets.

Proteomics International has completed an important milestone towards the development of a companion diagnostic (CDx) test with the validation of several of its protein biomarkers.

The research team authenticated the panel of biomarkers after taking 508 highly curated disease and control samples. Seven biomarkers were validated at high stringency using the company's proprietary mass spectrometry approach.

The mass spectrometry data was then cross-validated using immunoassays in collaboration with the KTH Royal Institute of Technology, Sweden, and Merck Millipore. A further five biomarkers were validated at high stringency and these are available for out-licensing. The validation was supported by a grant from Commercialisation Australia.

Proteomics International managing director Richard Lipscombe said there was excellent correlation between the new mass spectrometry platform and the traditional gold standard test, essential because antibody assays are more readily accepted by the FDA. "By doing it as a diagnostic and showing that the whole approach works, we set the foundations to create tests for other medical conditions," Dr Lipscombe said.

The next stage of development is to create a test that can determine whether patients will get diabetic kidney disease before they develop the condition. "The Holy Grail is to predict who's going to get sick and who isn't and that's something that will come out of our study later in 2014." Dr Lipscombe said. "But in the short term we want a diagnostic test that is going to provide doctors with a more accurate, robust test."

The International Diabetes Foundation estimates that there are 382 million people living with diabetes and expect the number to rise significantly. Based on current statistics 10 to 15 per cent of all people with diabetes will die from kidney disease.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Proteomics International, inVentiv Health Sign Biosimilar Agreement
Partnership offers developers full service biosimilar expertise on a global scale.
Saturday, March 01, 2014
Scientific News
Integrated Omics Analysis
Studying multi-omics promises to give a more holistic picture of the organism and its place in its ecosystem, however despite the complexities involved those within the field are optimistic.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Overlooked Molecules Could Revolutionise our Understanding of the Immune System
Researchers have discovered that around one third of all the epitopes displayed for scanning by the immune system are a type known as ‘spliced’ epitopes.
Study Finds Key Regulator in Pulmonary Fibrosis
Researchers identify an enzyme that could open the way to therpies for chronic fatal lung disease.
NIH Study Determines Key Differences between Allergic and Non-Allergic Dust Mite Proteins
Researchers at NIH have uncovered factors that lead to the development of dust mite allergy and assist in the design of better allergy therapies.
Alzheimer’s-Linked Protein May Play Role in Schizophrenia
Researchers suggests a protein linked to cognitive decline in Alzheimer's also plays a role in genetic predisposition to schizophrenia.
Peptides vs. Superbugs
Scientists successfully develop a shuttle system made of liquid-crystalline nanomaterials that protect peptites.
Immune Approach Targets Humans Instead of Bacteria
Scientists show for the first time how bacterial superantigen toxins work, and how short peptides can block them and save lives.
Cocoa Compound Linked to Some Cardiovascular Biomarker Improvements
The study highlights the urgent need for large, long-term RCTs that improve understanding of how the short-term benefits of cocoa flavanol intake on cardiometabolic biomarkers may be translated into clinical outcomes.
Could 2D Mass Spec Breakthrough Lead to Medical Revolution?
Pharmaceutical research could be quicker and more precise, thanks to an innovative breakthrough in 2D mass spec from the University of Warwick.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos